Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
NasdaqCM - Nasdaq Real Time Price USD

Heron Therapeutics, Inc. (HRTX)

Compare
2.2200
-0.1700
(-7.11%)
At close: March 10 at 4:00:01 PM EDT
2.2990
+0.08
+(3.56%)
After hours: March 10 at 7:50:21 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Craig Alexander Collard CEO & Director 5.49k -- 1966
Ms. Ira Duarte Executive VP & CFO 636.89k -- 1969
Dr. William P. Forbes Pharm. D., Pharm.D. Executive VP & Chief Development Officer 734.62k -- 1962
Mr. Ryan Craig Vice President of Marketing -- -- --
Mr. Sean T. Ristine Senior Vice President of Human Resources -- -- 1970
Mr. Robert Sullivan Senior Vice President of Oncology Care Franchise & Commercial Operations -- -- 1978
Mr. Brett Fleshman Chief Business Officer -- -- --
Mr. Jeff Cohn J.D. Executive Director, Assistant General Counsel & Assistant Secretary -- -- --

Heron Therapeutics, Inc.

100 Regency Forest Drive
Suite 300
Cary, NC 27518
United States
(858) 251-4400 https://www.herontx.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
122

Description

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.

Corporate Governance

Heron Therapeutics, Inc.’s ISS Governance QualityScore as of March 1, 2025 is 3. The pillar scores are Audit: 5; Board: 3; Shareholder Rights: 1; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

May 5, 2025 at 12:30 PM UTC - May 9, 2025 at 12:30 PM UTC

Heron Therapeutics, Inc. Earnings Date

Recent Events

February 27, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

February 20, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

December 23, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

December 3, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 12, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 8, 2024 at 12:00 AM UTC

SC 13G: Tender Offer/Acquisition Reports

November 4, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

October 24, 2024 at 12:00 AM UTC

SC 13G: Tender Offer/Acquisition Reports

August 6, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

July 2, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers